Gyre Therapeutics (GYRE) Current Assets (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Current Assets data on file, last reported at $91.7 million in Q1 2026.

• Current Assets for Q1 2026 came in at $91.7 million, up 34.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $91.7 million (up 34.02% YoY), and the FY2025 annual result was $102.4 million, up 58.01% from the prior year.
• Current Assets eased to $91.7 million in Q1 2026 per GYRE's latest filing, from $102.4 million in the prior quarter.
• Over five years, Current Assets peaked at $102.4 million in Q4 2025 and troughed at $5.1 million in Q3 2023.
• A 5-year average of $57.1 million and a median of $57.2 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets sank 90.63% in 2023, then soared 967.99% in 2024.
• A 5-year view of Current Assets shows it stood at $49.7 million in 2022, then advanced by 15.24% to $57.2 million in 2023, then advanced by 13.22% to $64.8 million in 2024, then surged by 58.01% to $102.4 million in 2025, then slipped by 10.39% to $91.7 million in 2026.
• Business Quant data shows GYRE's Current Assets at $91.7 million in Q1 2026, $102.4 million in Q4 2025, and $98.6 million in Q3 2025.